Sophie Schmitz Managing Partner, Partners 4 Access
Sophie is a leading expert on rare diseases and orphan drugs. She is heavily involved in advising orphan drug clients on price and market access strategies, with the ultimate goal of optimizing their launch. In a 20-year career span, Sophie has worked in various pharmaceutical therapy areas and medical devices focusing on key product launches in both strategic planning & implementation.
Dr Edmund Pezalla CEO, Enlightment Bioconsult and former VP for Pharmaceutical Policy and Strategy, Aetna
Edmund is an innovator in payer strategy for pharma and device manufacturers. As VP for Pharmaceutical Policy and Strategy in Aetna, he developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna’s framework for innovative contracts, and developed Aetna’s public policy positions on drug and device coverage. He is active as a payer expert on a number of policy working groups including the New Drug Development Paradigm Project at MIT and was previously a Scholar-in-Residence at Duke-Margolis Health Policy Center in Washington, DC
Prasun Subedi Senior Director at Center for Health System Innovation and Leadership Patient and Health Impact, Pfizer
Webinar 1: Gene-therapy a revolution or evolution of healthcare?
In the first of three webinars held in November 2017, P4A provided historical context, understanding of what gene therapy is; its clinical and environmental challenges and whether it has the potential to truly revolutionise the healthcare environment.
If you missed the event, you can download the webinar here.